The polygenic risk in schizophrenia: assessing GWASs and evaluating Clozapine, ECT and other treatment modalities

在线阅读 下载PDF 导出详情
摘要 Researchshowsthatthemortalityrateamongpeoplewithschizophreniaisuptofourtimeshigherthanthatinthegeneralpopulation.Thesubsequenthighcomorbiditiesandsocietalcostofschizophrenianecessitatefindingbetter,moreeffectivetreatmentsandstrategiesforprevention.Oneofthecurrentobstaclesarethecomplicatedgeneetiologiesthatareinvolvedinthepathophyslologyofschizophrenia.Sofar,anincreasingnumberofclinicalandexperimentalstudiesshowlinksbetweenschizophreniatreatmentandgeneticconditions.Here,weanalyzetheliteratureonschizophreniagenetics,withaparticularfocusonthebrain,themindandenvironmentalinsults.Anoverlapofschlzophrenlawithotherpsychoticdisordershasalsobeentakenintoaccuntwithanattempttofindaparallelrelationshipbetweengeneticsandtreatment.Finally,wesummarizeallthepresent-daytreatmentoptionsforschizophrenialikeclozapineandelectroconvulslvetherapyandalsotakeintoconsiderationtherelativelyunexploredroleoftraditionalChinesemedicine.
机构地区 不详
出处 《TMR生命研究》 2019年1期
出版日期 2019年01月11日(中国期刊网平台首次上网日期,不代表论文的发表时间)
  • 相关文献